HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohata, T. Articles by Wanibuchi, Y. Search for Related Content PubMed PubMed Citation Articles by Ohata, T. Articles by Wanibuchi, Y. Related Collections Valve disease

Ann Thorac Surg 2001;71:S240-S243
© 2001 The Society of Thoracic Surgeons

---

Valvular bioprostheses over 15 years

Comparison of durability of bioprostheses in tricuspid and mitral positions

^a Division of Cardiovascular Surgery, Mitsui Memorial Hospital, Tokyo, Japan
^b Clinical Laboratory, Mitsui Memorial Hospital, Tokyo, Japan

Address reprint requests to Dr Ohata, Division of Cardiovascular Surgery, Osaka Police Hospital, 10-31 Kitayama-cho, Tennoji-ku, Osaka 543-0035, Japan
e-mail: tohata{at}aol.com

Presented at the VIII International Symposium on Cardiac Bioprostheses, Cancun, Mexico, Nov 3–5, 2000.

Background. Few reports have assessed differences in the durability of mitral and tricuspid bioprostheses after simultaneous implantation of the same bioprosthesis in both positions. We investigated the long-term outcome after simultaneous mitral valve replacement (MVR) and tricuspid valve supraannular implantation (TVSI) with the Carpentier-Edwards bioprostheses in patients with severe tricuspid regurgitation and advanced mitral valve disease.

Methods. Between 1982 and 1998, 37 patients in our hospital underwent MVR and TVSI with Carpentier-Edwards bioprostheses. The mean age of the patients was 55 ± 11 years. The average postoperative follow-up was 7.9 ± 4.5 years after surgery (range 0 to 14.6 years, 315.1 patient-years). The follow-up rate was 100%. We evaluated the actuarial survival rate, the actuarial freedom from structural valve deterioration (SVD) and reoperation, and postoperative complications.

Results. The overall actuarial survival rate at 13 years after the operation was 69% ± 31%. The actuarial freedom from SVD and reoperation in the mitral and tricuspid positions were 78 ± 22 and 100% and 70 ± 30 and 90% ± 10% (p = 0.03), respectively. No patient had systemic or pulmonary thromboembolism, or complications associated with fatal arrhythmia.

Conclusions. These results suggest that the bioprostheses in the tricuspid position yield significantly better long-term results than those in the mitral position after simultaneous MVR and TVSI.

This article has been cited by other articles:

				S. Guhathakurta and K. M Cherian Triple Valve Replacement with Carpentier-Edwards Bioprostheses Asian Cardiovasc Thorac Ann, December 1, 2004; 12(4): 369 - 371. [Abstract] [Full Text] [PDF]

				N. A G Solomon, R. C H Lim, P. Nand, and K. J Graham Tricuspid Valve Replacement: Bioprosthetic or Mechanical Valve? Asian Cardiovasc Thorac Ann, June 1, 2004; 12(2): 143 - 148. [Abstract] [Full Text] [PDF]

				M. Carrier, Y. Hebert, M. Pellerin, D. Bouchard, L. P. Perrault, R. Cartier, A. Basmajian, P. Page, and N. C. Poirier Tricuspid valve replacement: an analysis of 25 years of experience at a single center Ann. Thorac. Surg., January 1, 2003; 75(1): 47 - 50. [Abstract] [Full Text] [PDF]

				R. J. Shemin Tricuspid Valve Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1001 - 1015. [Full Text]